Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M718Revenue $M17.3Net Margin (%)-173.7Z-Score-6.9
Enterprise Value $M717EPS $-0.6Operating Margin %-177.2F-Score3
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-173.7Higher ROA y-yN
Price/Book010-y EBITDA Growth Rate %-7.6Quick Ratio2.6Cash flow > EarningsY
Price/Sales39.85-y EBITDA Growth Rate %7.3Current Ratio2.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-61.6Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M60.1ROI % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 12.1215%New holding, 59700 sh.59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
BCRX George Soros 2014-03-3159,7000.10.01New Buy
Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2014-07-01Sell3,125$13-10.31view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-23Sell3,125$12.49-6.65view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-17Sell3,125$12-2.83view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-14Sell3,125$11.243.74view
LEE KENNETH B JRDirector 2014-03-06Sell12,665$12.69-8.12view
STAAB THOMAS R IISenior Vice President and CFO 2014-03-04Sell3,000$12.69-8.12view
Babu Yarlagadda SSenior VP - Drug Discovery 2014-03-04Sell40,642$12.57-7.24view
Barnes Alane PVP, General Counsel & Corp Sec 2014-03-04Sell40,734$12.63-7.68view
ABERCROMBIE GEORGE BDirector 2013-11-12Buy3,000$6.1988.37view
BAKER FELIX10% Owner 2013-08-01Buy1,136,364$4.4165view

Press Releases about BCRX :

    Quarterly/Annual Reports about BCRX:

    News about BCRX:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 


    More From Other Websites
    BioCryst to Announce Second Quarter 2014 Financial Results August 5 Jul 22 2014
    BioCryst to Announce Second Quarter 2014 Financial Results August 5 Jul 22 2014
    Anacor Pharmaceuticals, Inc. (ANAC) in Focus: Stock Surges 6.76% Jul 22 2014
    Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 7.52% Jul 17 2014
    Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% Jul 14 2014
    Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock up 8.37% Jul 10 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 01 2014
    NIAID exercises option under agreement with BioCryst Jun 23 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 23 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 05 2014
    6 stocks to watch Jun 04 2014
    BioCryst Announces Exercise of Over-Allotment Option and Completion of Public Offering Jun 03 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 03 2014
    BioCryst to Present at Two Upcoming Investor Conferences Jun 02 2014
    BioCryst 10M share Secondary priced at $10.00 May 28 2014
    BioCryst Pharmaceuticals Prices Public Offering of Common Stock May 28 2014
    BioCryst Pharmaceuticals (BCRX) Soars: Stock Adds 10.9% in Session May 28 2014
    BioCryst says has sufficient resources to fund operations beyond 2015 May 27 2014
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events May 27 2014
    BioCryst files to sell $100M in common stock May 27 2014
    BioCryst Commences Public Offering of Common Stock May 27 2014
    BioCryst rises on midstage study results May 27 2014
    BioCryst hereditary disorder drug succeeds in trial, shares jump May 27 2014
    BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model... Mar 03 2014
    BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results Mar 01 2014
    BioCryst Reports Fourth Quarter and Full Year 2013 Financial Results Feb 26 2014
    Wall Street holds near record high, yuan weaker Feb 25 2014
    US STOCKS-Wall St turns higher as retail stocks rally Feb 25 2014
    US STOCKS-Wall St falls modestly, but retail stocks rally Feb 25 2014
    BioCryst Announces Peramivir NDA Acceptance by the FDA Feb 25 2014
    US STOCKS-Futures slip, but Home Depot rises in premarket Feb 25 2014
    US STOCKS-Futures slip; results lift Home Depot in premarket Feb 25 2014
    BioCryst to Present at Three Upcoming Investor Conferences Feb 20 2014
    BioCryst to Announce Fourth Quarter and 2013 Financial Results February 26 Feb 12 2014
    BioCryst to Present at J.P. Morgan Healthcare Conference Jan 02 2014
    BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Marburg Virus... Dec 30 2013
    BioCryst Files Peramivir NDA for the Treatment of Influenza Dec 20 2013
    BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary... Nov 07 2013
    BioCryst Provides Corporate Update and Reports Third Quarter 2013 Financial Results Nov 05 2013

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide